Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT Combined With Radiotherapy for Advanced HCC
NCT03199807Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Adoptive Cell Transfer
01
Overview
Phase 2, open-label, single-arm trial of Neoantigen-reactive T cells in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Number of participants with Adverse Events up to 6 months. Status: unknown.
02
Drugs
Neoantigen-reactive T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03199807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199807.